1-4 of 4
Charlotta Liljebris
Close
Sort by
Journal Articles

XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use

Hans Lennernäs, Charlotta Liljebris, Magnus Brisander, Gérald Jesson, Per Andersson, Gunnar Larfors, Leif Stenke
Journal: Blood
Blood (2022) 140 (Supplement 1): 9652–9653.
https://doi.org/10.1182/blood-2022-169884
Published: 2022
Journal Articles

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

Gunnar Larfors, Hans Lennernäs, Charlotta Liljebris, Magnus Brisander, Gérald Jesson, Per Andersson, Leif Stenke
Journal: Blood
Blood (2022) 140 (Supplement 1): 6769–6770.
https://doi.org/10.1182/blood-2022-156487
Published: 2022
Journal Articles

Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer

Nina Mohell, PhD, Charlotta Liljebris, PhD, Jessica Alfredsson, PhD, Ylva Lindman, MSc, Maria Uustalu, MSc, Thomas Uhlin, BSc, Mats R.H. Linderholm, MD, PhD, Klas G. Wiman, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1806.
https://doi.org/10.1182/blood.V116.21.1806.1806
Published: 2010
Journal Articles

Further Preclinical Studies with APR-246, a Novel Anticancer Compound Currently in Clinical Trials for Hematological Malignancies and Prostate Cancer.

Nina Mohell, PhD, Charlotta Liljebris, PhD, Jessica Alfredsson, PhD, Ylva Lindman, MSc, Maria Uustalu, MSc, Klas G Wiman, PhD, MD, Thomas Uhlin, BSc
Journal: Blood
Blood (2009) 114 (22): 3773.
https://doi.org/10.1182/blood.V114.22.3773.3773
Published: 2009